Savara Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Savara non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-11.3%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-11.3%
Rendimento futuro dei dividendi	n/a
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05

Savara: They Failed Once, But They Are Trying Again

Jun 07

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Mar 17

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Feb 26

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

Nov 24

Savara EPS misses by $0.01

Nov 05

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di SVRA siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di SVRA siano aumentati.

Rendimento dei dividendi rispetto al mercato

Savara Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di SVRA rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (SVRA)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.4%
Media del settore (Biotechs)	2.1%
Analista previsionale (SVRA) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di SVRA rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di SVRA rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di SVRA per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché SVRA non ha segnalato alcun pagamento.

Savara Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Savara Appoints Braden Parker as Chief Commercial Officer

Savara: Trial Successful, But I'm Only Half Convinced

Price target increased by 19% to US$10.71

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

Savara: The Binary Bet On Phase 3 Data

Savara Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Savara Inc., Annual General Meeting, Jun 06, 2024

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024

No longer forecast to breakeven

New minor risk - Profitability

Chairman & CEO recently sold US$396k worth of stock

Forecast to breakeven in 2026

Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

New minor risk - Profitability

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

New minor risk - Shareholder dilution

New minor risk - Share price stability

Savara Inc. has completed a Follow-on Equity Offering in the amount of $79.994334 million.

Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis

Independent Director recently bought US$259k worth of stock

No longer forecast to breakeven

Price target increased by 21% to US$4.60

Savara Inc. Announces New Leadership Appointments

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara Inc. Announces New Leadership Appointments

Independent Director recently bought US$56k worth of stock

Forecast to breakeven in 2025

Independent Director recently bought US$82k worth of stock

Independent Director recently bought US$68k worth of stock

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Independent Director recently bought US$187k worth of stock

Independent Director recently bought US$142k worth of stock

Savara Announces Resignation of Badrul Chowdhury as Chief Medical Officer, Effective on September 9, 2022

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Savara GAAP EPS of -$0.06 in-line

Independent Director recently bought US$138k worth of stock

Savara Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Savara Inc., Annual General Meeting, Jun 02, 2022

Price target increased to US$4.50

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Independent Director recently bought US$64k worth of stock

Independent Director recently bought US$215k worth of stock

Independent Director recently bought US$176k worth of stock

Independent Director recently bought US$115k worth of stock

Is Savara (NASDAQ:SVRA) A Risky Investment?

Savara Inc. Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Savara Inc.(NasdaqGS:SVRA) dropped from Russell 3000E Value Index

Savara: They Failed Once, But They Are Trying Again

Independent Director recently bought US$81k worth of stock

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Savara Inc. has completed a Follow-on Equity Offering in the amount of $113.011275 million.

Revenue and earnings beat expectations

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Chairman & CEO recently bought US$50k worth of stock

New 90-day high: US$2.06

New 90-day high: US$1.97

New 90-day high: US$1.57

Price target lowered to US$2.67

Savara Inc. Provides Update on Molgradex in aPAP and the Phase 3 IMPALA 2 Trial

Savara Inc. Announces CEO Change

New 90-day high: US$1.44

Price target lowered to US$3.83

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

New 90-day low: US$1.00

Earnings beat expectations

Savara EPS misses by $0.01

New 90-day low: US$1.07

New 90-day low: US$1.09

Price target lowered to US$4.43

Savara Inc. Announces Management Changes